Healthcare Providers and Services
Company Overview of Miraca Life Sciences, Inc.
Miraca Life Sciences, Inc. operates clinical pathology laboratories that provide diagnostic services in the fields of dermatology, gastroenterology, hematology, and urology in the United States. It focuses on the development of a blood-based diagnostics platform to address unmet clinical needs in the gastrointestinal cancer spectrum that range from screening and diagnosis to prognosis and therapeutic guidance. The company also provides urologic pathology services, including microscopy and immunohistochemistry with integrated molecular diagnostic services; EoGenius test that helps diagnose and monitor patients with eosinophilic esophagitis; and UroVysion, a deoxyribonucleic acid-based urine t...
6655 North MacArthur Boulevard
Irving, TX 75039
Founded in 1996
Key Executives for Miraca Life Sciences, Inc.
Interim Chief Executive Officer
Chief Medical Officer and Executive Vice President of Operations
Compensation as of Fiscal Year 2017.
Miraca Life Sciences, Inc. Key Developments
Miraca Life Sciences Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®
May 23 17
Miraca Life Sciences has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to now seven biologic drugs that treat inflammatory bowel disease (IBD). In the United States, InformTx is the only TDM (with anti-drug antibodies) available for Cimzia® (certolizumab pegol), Stelara® (ustekinumab), and Simponi® (golimumab). The company also continues to offer TDM for Remicade® (infliximab), Humira® (adalimumab), and Entyvio® (vedolizumab). The InformTx report is unique in that it provides clinicians with quantitative test results, historical test result data, and guidance from the most up-to-date peer-reviewed scientific literature. Testing measures the level of Inflectra as well as patient-developed antibodies to Inflectra. Miraca Life Sciences uses laboratory-validated ELISA technology for InformTx TDM, and testing results are reported within five days.
Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences
Dec 1 16
Miraca Life Sciences has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab). Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since launching in June this year, the company’s InformTx TDM service is the first time that TDM has been available in the United States for Cimzia and Entyvio. Unique for TDM in the United States, the InformTx report provides clinicians with quantitative test results, historical test result data, and guidance from the most up-to-date peer-reviewed scientific literature. Miraca Life Sciences uses laboratory-validated ELISA technology for InformTx TDM, and testing results are reported within five days.
Miraca Life Sciences to Market Theradiag's LISA TRACKER® Range in US Market
Jun 16 16
Theradiag announced that four tests from its LISA TRACKER® range have been launched in the US market, under the licensing agreement with Miraca Life Sciences that was announced in November 2015. Miraca Life Sciences will start to market and promote four tests under the name “InformTx™” that utilize technology and raw materials from Theradiag's LISA TRACKER® range. These four biotherapy monitoring tests (Infliximab/Remicade®, Adalimumab/Humira®, Certolizumab/Cimzia® and Vedolizumab/Entyvio®) deal mainly with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The launch of InformTx™ by Miraca Life Sciences marks the first time that monitoring has been available in the US market for Certolizumab and Vedolizumab. Theradiag will sell the required materials and will receive royalties on Miraca Life Sciences' sales in the USA.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2017